COHEN & STEERS INC (CNS) Fundamental Analysis & Valuation

NYSE:CNS • US19247A1007

64.25 USD
-0.71 (-1.09%)
At close: Mar 9, 2026
64.25 USD
0 (0%)
After Hours: 3/9/2026, 4:15:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall CNS gets a fundamental rating of 5 out of 10. We evaluated CNS against 242 industry peers in the Capital Markets industry. CNS has an excellent profitability rating, but there are some minor concerns on its financial health. CNS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. CNS Profitability Analysis

1.1 Basic Checks

  • In the past year CNS was profitable.
  • In the past year CNS has reported a negative cash flow from operations.
  • In the past 5 years CNS has always been profitable.
  • CNS had a positive operating cash flow in 4 of the past 5 years.
CNS Yearly Net Income VS EBIT VS OCF VS FCFCNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

1.2 Ratios

  • With an excellent Return On Assets value of 20.48%, CNS belongs to the best of the industry, outperforming 97.11% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 29.83%, CNS belongs to the top of the industry, outperforming 95.04% of the companies in the same industry.
  • CNS has a better Return On Invested Capital (24.42%) than 98.35% of its industry peers.
Industry RankSector Rank
ROA 20.48%
ROE 29.83%
ROIC 24.42%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNS Yearly ROA, ROE, ROICCNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • Looking at the Profit Margin, with a value of 29.73%, CNS is in the better half of the industry, outperforming 69.42% of the companies in the same industry.
  • In the last couple of years the Profit Margin of CNS has grown nicely.
  • CNS has a Operating Margin of 33.83%. This is in the better half of the industry: CNS outperforms 63.64% of its industry peers.
  • CNS's Operating Margin has declined in the last couple of years.
  • CNS has a Gross Margin of 88.60%. This is amongst the best in the industry. CNS outperforms 93.39% of its industry peers.
  • CNS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.83%
PM (TTM) 29.73%
GM 88.6%
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
CNS Yearly Profit, Operating, Gross MarginsCNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CNS Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CNS Yearly Shares OutstandingCNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CNS Yearly Total Debt VS Total AssetsCNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • CNS has an Altman-Z score of 9.17. This indicates that CNS is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 9.17, CNS belongs to the top of the industry, outperforming 91.74% of the companies in the same industry.
  • CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.17
ROIC/WACCN/A
WACCN/A
CNS Yearly LT Debt VS Equity VS FCFCNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.3 Liquidity

  • CNS has a Current Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.79, CNS is doing worse than 62.81% of the companies in the same industry.
  • A Quick Ratio of 0.79 indicates that CNS may have some problems paying its short term obligations.
  • CNS has a worse Quick ratio (0.79) than 62.40% of its industry peers.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.79
CNS Yearly Current Assets VS Current LiabilitesCNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CNS Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 5.80% over the past year.
  • The Earnings Per Share has been growing slightly by 3.74% on average over the past years.
  • The Revenue has been growing slightly by 7.04% in the past year.
  • The Revenue has been growing slightly by 5.73% on average over the past years.
EPS 1Y (TTM)5.8%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%3.85%
Revenue 1Y (TTM)7.04%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%17.21%

3.2 Future

  • CNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.66% yearly.
  • CNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.70% yearly.
EPS Next Y8.82%
EPS Next 2Y10.9%
EPS Next 3Y8.22%
EPS Next 5Y8.66%
Revenue Next Year7.29%
Revenue Next 2Y9.14%
Revenue Next 3Y7.24%
Revenue Next 5Y6.7%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CNS Yearly Revenue VS EstimatesCNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
CNS Yearly EPS VS EstimatesCNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

2

4. CNS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 20.73, which indicates a rather expensive current valuation of CNS.
  • CNS's Price/Earnings ratio is a bit more expensive when compared to the industry. CNS is more expensive than 66.12% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.29. CNS is valued slightly cheaper when compared to this.
  • CNS is valuated rather expensively with a Price/Forward Earnings ratio of 19.05.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CNS is on the same level as its industry peers.
  • The average S&P500 Price/Forward Earnings ratio is at 24.60. CNS is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 20.73
Fwd PE 19.05
CNS Price Earnings VS Forward Price EarningsCNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than 75.62% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.34
CNS Per share dataCNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)2.35
PEG (5Y)5.54
EPS Next 2Y10.9%
EPS Next 3Y8.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. CNS Dividend Analysis

5.1 Amount

  • CNS has a Yearly Dividend Yield of 4.05%, which is a nice return.
  • CNS's Dividend Yield is comparable with the industry average which is at 6.65.
  • Compared to an average S&P500 Dividend Yield of 1.82, CNS pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.05%

5.2 History

  • The dividend of CNS decreases each year by -7.12%.
  • CNS has paid a dividend for at least 10 years, which is a reliable track record.
  • The dividend of CNS decreased in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
CNS Yearly Dividends per shareCNS Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3

5.3 Sustainability

  • 76.25% of the earnings are spent on dividend by CNS. This is not a sustainable payout ratio.
DP76.25%
EPS Next 2Y10.9%
EPS Next 3Y8.22%
CNS Yearly Income VS Free CF VS DividendCNS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
CNS Dividend Payout.CNS Dividend Payout, showing the Payout Ratio.CNS Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

CNS Fundamentals: All Metrics, Ratios and Statistics

COHEN & STEERS INC

NYSE:CNS (3/9/2026, 4:15:00 PM)

After market: 64.25 0 (0%)

64.25

-0.71 (-1.09%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)01-22
Earnings (Next)04-14
Inst Owners56.27%
Inst Owner Change-2.29%
Ins Owners23%
Ins Owner Change5.46%
Market Cap3.30B
Revenue(TTM)553.87M
Net Income(TTM)164.16M
Analysts48
Price Target71.91 (11.92%)
Short Float %7.01%
Short Ratio5.95
Dividend
Industry RankSector Rank
Dividend Yield 4.05%
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.25%
Div Incr Years2
Div Non Decr Years2
Ex-Date03-09
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.39%
Min EPS beat(2)-4.27%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-0.86%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)3
Avg EPS beat(8)-0.49%
EPS beat(12)5
Avg EPS beat(12)0.41%
EPS beat(16)9
Avg EPS beat(16)1.94%
Revenue beat(2)1
Avg Revenue beat(2)-0.16%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)-2.44%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.82%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.69%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.17%
Valuation
Industry RankSector Rank
PE 20.73
Fwd PE 19.05
P/S 5.98
P/FCF N/A
P/OCF N/A
P/B 6
P/tB 6.23
EV/EBITDA 16.34
EPS(TTM)3.1
EY4.82%
EPS(NY)3.37
Fwd EY5.25%
FCF(TTM)-1.83
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS10.74
BVpS10.71
TBVpS10.32
PEG (NY)2.35
PEG (5Y)5.54
Graham Number27.33
Profitability
Industry RankSector Rank
ROA 20.48%
ROE 29.83%
ROCE 31.59%
ROIC 24.42%
ROICexc 29.28%
ROICexgc 32.82%
OM 33.83%
PM (TTM) 29.73%
GM 88.6%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
F-Score5
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 63.99%
Cap/Sales 1.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.79
Altman-Z 9.17
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.8%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%3.85%
EPS Next Y8.82%
EPS Next 2Y10.9%
EPS Next 3Y8.22%
EPS Next 5Y8.66%
Revenue 1Y (TTM)7.04%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%17.21%
Revenue Next Year7.29%
Revenue Next 2Y9.14%
Revenue Next 3Y7.24%
Revenue Next 5Y6.7%
EBIT growth 1Y15.71%
EBIT growth 3Y-4.78%
EBIT growth 5Y3.6%
EBIT Next Year-2.4%
EBIT Next 3Y14.61%
EBIT Next 5Y11.96%
FCF growth 1Y-194.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-171.97%
OCF growth 3YN/A
OCF growth 5YN/A

COHEN & STEERS INC / CNS FAQ

What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CNS.


What is the valuation status for CNS stock?

ChartMill assigns a valuation rating of 2 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.


Can you provide the profitability details for COHEN & STEERS INC?

COHEN & STEERS INC (CNS) has a profitability rating of 7 / 10.


Can you provide the financial health for CNS stock?

The financial health rating of COHEN & STEERS INC (CNS) is 5 / 10.


What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?

The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 8.82% in the next year.